NEJM: Preventive role in patients with undetermined history of embolism stroke

For patients with embolism stroke with an uncertain source, we conducted a multicenter, randomized, double-blind trial of The Darbiggroup twice a day with a dose of 150 mg or 110 mg per day with aspirin 100 mgThe main result is a recurrence of strokeThe main safety result is a haemorrhagea total of 5,390 patients were selected at 564 locations and randomly assigned to take dabiga (2695 cases) or aspirin (2695 cases)During the 19-month median follow-up period, 177 patients (6.6%) in the Darbiga group (4.1 per cent per year) had a recurrent stroke, and 207 (7.7 per cent) in the aspirin group (4.8 per cent per year) had stroke (risk ratio of 0.85; 95 per cent confidence interval of 0.69 to 1.03; P s 0.10)Ischemic stroke occurred in 172 patients (4.0 per cent per year) and 203 patients (4.7 per cent per year) (risk ratio, 0.84; 95% CI, 0.68 to 1.03), respectivelyIn the Dabiga group, 77 patients (1.7 per cent per year) had haemorrhage, and in the aspirin group, 64 patients (1.4 per cent per year) had haemorrhage (risk ratio, 1.19; 95% CI, 0.85 to 1.66)Clinically related non-significant bleeding occurred in 70 patients (1.6% per year) and 41 patients (0.9% per year), respectivelyin patients with an undetermined history of embolism stroke in the recent past, Darbiggroup was no better at preventing recurrent stroke than aspirinThe incidence of hemorrhage in the Darbiga group was no higher than that of aspirin groups, but there were more clinically related non-hemorrhage events in the Darbygar group